만성 요통 : 시장 인사이트, 역학 및 시장 예측(2036년)

Chronic Lower Back Pain (CLBP) Insights and Trends

• According to DelveInsight's analysis, CLBP market size was found to be ~USD 9,700 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

In 2025, opioids accounted for approximately 30% of CLBP treatment use in the US, reflecting continued reliance on opioid analgesics for persistent or refractory pain despite increasing efforts to shift toward non-opioid and non-pharmacological alternatives.

• CLBP Prevalence rose from under 5% in the early 1990s to over 10% by the mid-2000s in tracking studies, and 2022 survey data put CLBP at roughly 28% of US adults, which accounts for a disproportionately high clinical and socioeconomic burden due to persistent pain, recurrent flare-ups, substantial physical disability, and long-term activity limitation.
• Moderate CLBP represents the largest diagnosed subgroup, followed by mild CLBP, while severe CLBP, despite being the smallest segment, accounts for substantially higher healthcare utilization and intensive treatment.
• The cell and gene therapy market in CLBP is an emerging segment focused on single-dose, potentially durable treatments that aim to promote disc regeneration, tissue repair, neuroprotection, and disease modification, with candidates such as rebonuputemcel (IDCT), rexlemestrocel-L, BRTX-100, olastrocel, KLS-2031, and others targeting underlying disease mechanisms beyond symptomatic pain relief.
• Intradiscal injection remains the leading delivery route for regenerative CLBP therapies, enabling direct targeting of the degenerated disc. At the same time, newer systemic and minimally invasive approaches aim to improve accessibility and durability.
• CLBP treatment includes corticosteroids, muscle relaxants, acetaminophen, and neuropathic agents, with discogenic pain accounting for ~50% of US prescription opioid use.
• Therapies such as Mesoblast's rexlemestrocel-L are being developed for chronic discogenic pain and degenerative spinal conditions, to achieve disease modification beyond symptomatic pain relief. These approaches are currently administered through minimally invasive injection-based procedures rather than oral delivery.
• Among patients with moderate-to-severe CLBP, a clinically significant subgroup presents with Modic Type 1 changes, an inflammatory vertebral endplate phenotype associated with persistent pain and poorer outcomes. This subgroup represents an emerging therapeutic target, with investigational therapies such as PP353 (micronized linezolid) being evaluated to address this unmet need.
• High opioid utilization in the US and Europe, despite growing guideline caution, underscores the need for disease-modifying alternatives such as IDCT, which could address the underlying DDD pathology while providing durable pain relief and potentially slowing or reversing disc degeneration.

Chronic Lower Back Pain (CLBP) Market Size and Forecast in the 7MM

• 2025 Chronic Lower Back Pain (CLBP) Market Size: ~USD 9,700 million
• Chronic Lower Back Pain (CLBP) Growth Rate (2026-2036): ~5.4% CAGR

DelveInsight's 'Chronic Lower Back Pain (CLBP)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of CLBP, historical and forecasted epidemiology, as well as the CLBP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chronic Lower Back Pain (CLBP) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates CLBP patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis. It provides an in-depth market size assessment and growth rate projections (historical & forecast 2022-2036) across global regions. The report highlights key unmet medical needs in CLBP and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chronic Lower Back Pain (CLBP) Market

• Increasing prevalence of CLBP and an aging population

The growing burden of degenerative spinal conditions, sedentary lifestyles, obesity, and age-related musculoskeletal disorders is expanding the CLBP patient population and increasing demand for effective long-term treatment options.

• Growing preference for non-opioid and minimally invasive therapies

Increasing concerns regarding opioid dependence, adverse effects, and long-term use are accelerating the shift toward non-opioid pharmacological therapies, regenerative medicine, neuromodulation, and minimally invasive interventions.

• Advances in treatment modalities and personalized pain management

Continued innovation in pharmacological therapies, biologics, regenerative approaches, and device-based interventions is expanding treatment options for patients with persistent or refractory CLBP and supporting market growth.

Chronic Lower Back Pain (CLBP) Understanding and Treatment Algorithm

Chronic Lower Back Pain (CLBP) Overview and Diagnosis

Chronic low back pain (CLBP) is defined as pain localized to the lower back that persists for 12 weeks or longer, often continuing beyond the expected period of tissue healing. It is one of the leading causes of disability worldwide and is associated with significant physical, psychological, and socioeconomic burden, particularly among older adults. CLBP may arise from degenerative spinal disorders, mechanical abnormalities, nerve compression, or other underlying conditions, although a specific cause is often difficult to identify. Diagnosis is primarily based on a detailed medical history and physical examination to differentiate mechanical from non-mechanical causes, with imaging modalities such as X-ray, magnetic resonance imaging (MRI), or computed tomography (CT) reserved for patients with persistent symptoms, neurological deficits, or suspected serious underlying pathology.

Current Chronic Lower Back Pain (CLBP) Treatment Landscape

Managing CLBP involves a multimodal approach aimed at reducing pain, improving function, and enhancing quality of life. Initial treatment typically includes non-pharmacological interventions alongside non-opioid analgesics such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors. At the same time, long-term use of muscle relaxants is generally discouraged due to limited efficacy and safety concerns. For patients with moderate-to-severe pain who do not achieve adequate relief with first-line therapies, opioid analgesics may be considered under careful medical supervision. Currently, oxycodone (XTAMPZA ER), an extended-release opioid analgesic, and buprenorphine buccal film (BELBUCA), a partial μ-opioid receptor agonist, are approved treatment options for managing severe chronic pain requiring around-the-clock, long-term opioid therapy when alternative treatments are inadequate.

Chronic Lower Back Pain (CLBP) Unmet Needs

The section "unmet needs of CLBP" outlines critical gaps between the current state of patient care and diagnosis and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited long-term efficacy and need for durable disease control

2. Heavy reliance on opioids due to limited long-term alternatives

3. High patient heterogeneity and variable treatment response

4. Diagnostic uncertainty and imaging-symptom disconnect, and others.....

Chronic Lower Back Pain (CLBP) Epidemiology

Key Findings from Chronic Lower Back Pain (CLBP) Epidemiological Analysis and Forecast

• The prevalent cases of CLBP in the 7MM were 148 million in 2025, rising at a CAGR of 0.8% during the study period; this is expected to rise by 2036. This growth is primarily driven by population aging, increasing burden of degenerative spinal disorders, sedentary lifestyles, and rising obesity rates, along with improved disease recognition, greater healthcare utilization, and enhanced diagnosis of chronic pain. In addition, the chronic and recurrent nature of CLBP, coupled with greater awareness among healthcare professionals and patients, continues to expand the patient population.
• Among the 7MM, the US accounted for ~50% (~76 million) of total prevalent CLBP cases in 2025; these cases are expected to increase throughout the forecast period.
• DDD is the leading cause of CLBP, driven by age-related spinal degeneration and cumulative mechanical stress.
• In the US, CLBP severity was predominantly moderate (~50%), followed by mild (~30%) and severe (~20%), indicating that most patients experience a clinically meaningful symptom burden.
• Moderate-to-severe CLBP had a higher treatment rate in the United States, with ~32 million treated cases in 2025, compared with ~6 million treated cases for mild CLBP. The treated cases across both severity groups are projected to increase through 2036.
• In the United States, among age-specific prevalent CLBP cases, patients aged 70 years and above accounted for 22 million cases, followed by those aged 50-59 in 2025, with both segments expected to increase by 2036.

Chronic Lower Back Pain (CLBP) Drug Analysis & Competitive Landscape

The CLBP drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, patents, collaborations, and strategic partnerships, key upcoming catalysts for each therapy, and their advantages, limitations, and recent developments. This section offers critical insights into the CLBP treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the CLBP therapeutics market.

Approved Therapies for Chronic Lower Back Pain (CLBP)

Oxycodone ER abuse-deterrent (XTAMPZA ER): Collegium Pharmaceutical

Oxycodone ER is Collegium's first product utilizing the DETERx technology platform. Oxycodone, a Schedule II opioid, is an abuse-deterrent, extended-release, oral formulation. It is formulated using a novel abuse-deterrent technology platform, DETERx, that provides extended-release delivery and is designed to deter abuse and misuse (e.g., crushing, chewing, heating, and injecting).

Oxycodone ER abuse-deterrent (XTAMPZA ER) is protected by 12 issued patents in the US, 1 granted and 2 pending applications in the European Patent Office. One issued US patent expired in 2025, and the remaining are projected to expire in 2030 and 2036. The pending patent applications in the US, if issued, would be projected to expire in 2030 and 2036.

VER-01 (EXILBY): VERTANICAL

VER-01 (EXILBY) is a first-in-class non-opioid treatment for CLBP. VER-01 (EXILBY) is an investigational standardized full-spectrum extract derived from the Cannabis sativa strain DKJ127 L., a proprietary plant genetics selected to provide a phytochemical profile tailored to chronic pain. Its composition includes a defined mixture of cannabinoids, terpenes, and other bioactive compounds selected for their potential relevance in pain modulation and associated symptoms.

Chronic Lower Back Pain (CLBP) Pipeline Analysis

Rexlemestrocel-L (MPC-06-ID): Mesoblast and Grunenthal

Rexlemestrocel-L is positioned as a potentially first-in-class, disease-modifying cell therapy for moderate-to-severe CLBP associated with DDD in patients who remain symptomatic despite conservative treatment. Unlike conventional symptomatic therapies, it targets underlying disc pathology and is administered as a single intradiscal injection. Phase III data demonstrating sustained pain reduction for up to 36 months, particularly in patients with shorter disease duration, support its potential for earlier use and reduced reliance on opioids or invasive procedures. Physician interest is also favorable, with 85% of surveyed pain specialists indicating they would likely recommend it based on clinical outcomes. It is in Phase III of clinical development.

Rebonuputemcel (IDCT): DiscGenics

Rebonuputemcel (IDCT) is a potentially first-in-class, allogeneic regenerative cell therapy designed to address underlying disc degeneration rather than provide symptomatic relief. Its off-the-shelf design, low immunogenicity, RMAT and Fast Track designations, and FDA-aligned Phase III PIVOT and CONFIRM programs strengthen its development profile. Early safety findings, including a recent favorable DSMB review, are reassuring but remain preliminary. Commercial potential is significant given the large unmet need in CLBP and the opportunity for a durable, disease-modifying treatment; however, efficacy remains uncertain due to the challenges of sham-controlled DDD trials, unproven long-term durability and manufacturing scalability, and competition from rexlemestrocel-L.

Chronic Lower Back Pain (CLBP) Key Players, Market Leaders and Emerging Companies

• VERTANICAL
• Collegium Pharmaceutical
• Eli Lilly
• Scilex Holding (Semnur Pharmaceuticals)
• Spine BioPharma
• DiscGenics
• Mesoblast
• Grunenthal
• Tris Pharma (Adneuris Therapeutics)
• BioRestorative Therapies
• Vertex Pharmaceuticals
• Stayble Therapeutics, and others

Chronic Lower Back Pain (CLBP) Drug Updates

• In July 2026, Mesoblast announced that it had achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase III randomized controlled trial of rexlemestrocel-L for CLBP associated with DDD.
• In June 2026, VERTANICAL anticipated the UK approval of VER-01 (EXILBY) by the end of the year (2026).
• In June 2026, VERTANICAL announced it had initiated an additional pivotal US Phase III trial to support a future FDA submission. The company also anticipates a first data read-out in 2027 and, subject to positive results, plans to submit an NDA in 2028.
• In June 2026, DiscGenics announced that the independent DSMB completed the planned safety review of the Phase III study evaluating rebonuputemcel for symptomatic lumbar DDD. After assessing the available safety data, the DSMB recommended that the trial continue without any modifications to the study protocol, in line with the FDA-approved safety monitoring plan.
• In May 2026, VERTANICAL announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to VER-01 for the treatment of CLBP.
• In March 2026, DiscGenics's CEO highlighted the launch of the FDA-approved Phase III Program for rebonuputemcel at the CG 2026 Musculoskeletal Conference.
• In August 2025, Spine BioPharma announced that the Phase III MODEL trial evaluating SB-01 for intradiscal treatment of patients with CLBP associated with DDD did not meet its primary endpoint of pain intensity and pain-related function at Month 6 post-treatment compared to sham control.

Chronic Lower Back Pain (CLBP) Market Outlook

CLBP management is primarily multimodal and function-focused, reflecting its heterogeneous mechanical, degenerative, neuropathic, and psychosocial etiology. Conservative care, including education, exercise, physiotherapy, weight management, and NSAIDs, remains foundational. At the same time, duloxetine, muscle relaxants, selected opioids, epidural injections, and surgery are used according to disease severity and treatment response. The market remains largely generic-dominated, with NSAIDs, acetaminophen, duloxetine, and established opioids widely used; however, limited durability, safety concerns, opioid dependence, and the symptomatic nature of existing therapies continue to create substantial unmet need.

The CLBP pipeline is increasingly focused on non-opioid, regenerative, disease-modifying, and targeted approaches to provide more durable pain and functional benefits. Late-stage candidates such as SP-102, IDCT, rexlemestrocel-L, SB-01, BRTX-100, and Olastrocel, alongside emerging approaches such as PP353, HYDRAFIL, retatrutide, and novel analgesics, could diversify treatment beyond conventional pharmacotherapy and repeated interventions. However, development remains challenging because of high placebo responses, long-term safety and durability requirements, manufacturing complexity, and reimbursement barriers, making clinical differentiation and durable functional improvement critical for successful adoption.

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM CLBP market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest CLBP market size. i.e., USD ~6,600 million in 2025.
• In 2036, among all CLBP therapies, amivantamab (RYBREVANT) +- lazertinib (LAZCLUZE) is expected to generate the highest revenue, followed by osimertinib (TAGRISSO), in the US.
• Emerging regenerative and disease-modifying therapies, including IDCT (Rebonuputemcel), Rexlemestrocel-L, SB-01, SP-102 (SEMDEXA), and BRTX-100, are expanding the treatment landscape by targeting the underlying pathology of chronic pain rather than providing symptomatic relief alone.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Lower Back Pain (CLBP) (2022-2036)

The CLBP pipeline includes therapies designed to provide durable pain relief, reduce inflammation, address nociceptive and neuropathic mechanisms, and overcome limitations of conventional analgesics and long-term opioid therapy. Emerging modalities include non-opioid analgesics, regenerative and cell-based therapies, targeted anti-inflammatory agents, gene therapies, and novel neuromodulation approaches, with the broader goal of improving pain control, physical function, mobility, and quality of life while reducing opioid dependence and treatment-related adverse effects.

• Glucocorticoid receptor agonists: Act through glucocorticoid receptor signaling to suppress local inflammation and reduce pain. SP-102 (SEMDEXA) is an injectable glucocorticoid formulation being developed for chronic lumbosacral radicular pain, offering a potentially differentiated epidural treatment with sustained local activity.
• GIP/GLP-1/glucagon receptor agonists: Target multiple metabolic pathways involved in weight reduction and may indirectly improve CLBP by reducing mechanical loading and obesity-associated inflammation. Retatrutide (LY3437943) is being evaluated in patients with overweight or obesity and CLBP, representing a metabolic approach to pain management.
• TGF-B1 antagonists: Target TGF-B1 signaling involved in disc degeneration and extracellular matrix remodeling, with the potential to address underlying disc pathology. Vicatertide (SB-01) is an intradiscal biologic being evaluated for CLBP associated with moderate-to-severe DDD.
• Allogeneic discogenic cell therapy: Uses donor-derived discogenic cells to support tissue repair, modulate inflammation, and potentially restore disc function. Rebonuputemcel (IDCT) is an intradiscal allogeneic cell therapy being developed for lumbar DDD, with the potential to provide durable benefits beyond symptomatic pain control.

Chronic Lower Back Pain (CLBP) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the CLBP drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of emerging CLBP therapies is expected to vary based on clinical efficacy, durability, safety, administration route, patient selection, physician familiarity, and reimbursement. SP-102 (SEMDEXA) may achieve relatively faster adoption due to its minimally invasive administration and established fit within the interventional pain pathway, while VER-01 (EXILBY), IDCT, rexlemestrocel-L, AMG0103, BRTX-100, retatrutide, cebranopadol, and PP353 are expected to see moderate uptake as their clinical differentiation and long-term benefits become established. SB-01, Olastrocel, and KLS-2031 may experience slower-to-moderate adoption as physicians and payers assess durability, safety, real-world outcomes, and cost-effectiveness. Overall, uptake is expected to build gradually, with broader adoption driven by meaningful functional improvement, reduced reliance on opioids or repeated interventions, and supportive reimbursement.

Detailed insights into emerging therapies' drug uptake are included in the report.

Market Access and Reimbursement of Approved Therapies in Chronic Lower Back Pain (CLBP)

The report also provides detailed insights on country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios for approved therapies, programs that make access easier and out-of-pocket costs more affordable, and insights on patients insured under federal or state government prescription drug programs.

Chronic Lower Back Pain (CLBP) Therapies Price Scenario & Trends

Pricing and analogue assessment of CLBP therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of CLBP Approved Drugs

For NSAIDs, the average cost of ibuprofen, diclofenac, and naproxen was considered, resulting in an estimated annual treatment cost of USD 78. For opioids, the average cost of tramadol, codeine, hydrocodone, and oxycodone was used, resulting in an estimated annual treatment cost of USD 189.

Industry Experts and Physician Views for Chronic Lower Back Pain (CLBP)

To keep up with CLBP market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on CLBP emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in CLBP, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Princeton Spine & Joint Center, University of North Carolina at Chapel Hill, University of Southern California, University Hospital Giessen, etc. were contacted. Their opinion helps understand and validate current and emerging CLBP therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in CLBP.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Chronic Lower Back Pain (CLBP), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of CLBP, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the CLBP market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM CLBP market.

Report Insights

• Chronic Lower Back Pain (CLBP) Patient Population Forecast
• Chronic Lower Back Pain (CLBP) Therapeutics Market Size
• Chronic Lower Back Pain (CLBP) Pipeline Analysis
• Chronic Lower Back Pain (CLBP) Market Size and Trends
• Chronic Lower Back Pain (CLBP) Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Chronic Lower Back Pain (CLBP) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Chronic Lower Back Pain (CLBP) Treatment Addressable Market (TAM)
• Chronic Lower Back Pain (CLBP) Competitive Landscape
• Chronic Lower Back Pain (CLBP) Major Companies Insights
• Chronic Lower Back Pain (CLBP) Price Trends and Analogue Assessment
• Chronic Lower Back Pain (CLBP) Therapies Drug Adoption/Uptake
• Chronic Lower Back Pain (CLBP) Therapies Peak Patient Share Analysis

Report Assessment

• Chronic Lower Back Pain (CLBP) Current Treatment Practices
• Chronic Lower Back Pain (CLBP) Unmet Needs
• Chronic Lower Back Pain (CLBP) Clinical Development Analysis
• Chronic Lower Back Pain (CLBP) Emerging Drugs Product Profiles
• Chronic Lower Back Pain (CLBP) Market Attractiveness
• Chronic Lower Back Pain (CLBP) Qualitative Analysis (SWOT and Conjoint analysis)

FAQs:

Market Insights

• What was the CLBP market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of CLBP?
• What are the disease risks, burdens, and unmet needs of CLBP? What will be the growth opportunities across the 7MM concerning the patient population with CLBP?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of CLBP? What are the current guidelines for treating CLBP in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CLBP market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Lower Back Pain (CLBP)

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences and Meetings
• 4.3. Key Transactions and Collaborations
• 4.4. News Flows

5. Epidemiology and Market Forecast Methodology of Chronic Lower Back Pain (CLBP)

6. Chronic Lower Back Pain (CLBP) Market Overview at a Glance

• 6.1. Clinical Landscape (Analysis by Phase, Route of Administration [RoA], and Molecule Type)
• 6.2. Market Share (%) Distribution of CLBP by Therapies in 2025 in the 7MM
• 6.3. Market Share (%) Distribution of CLBP by Therapies in 2036 in the 7MM

7. Disease Background and Overview of Chronic Lower Back Pain (CLBP)

• 7.1. Introduction
• 7.2. Signs and Symptoms Related to CLBP
• 7.3. Pathophysiology
• 7.4. Classification of CLBP
• 7.5. Risk Factors Related to CLBP
• 7.6. Evaluation of Pain in CLBP
• 7.7. Diagnosis of CLBP
  • 7.7.1. Differential Diagnosis
• 7.8. Treatment
  • 7.8.1. Treatment Algorithm
• 7.9. Diagnostic and Management Guidelines Related to CLBP
  • 7.9.1. Low Back Pain and Sciatica: Assessment and Management: NICE Guidelines (2026)
  • 7.9.2. American Academy of Family Physicians: Chronic Low Back Pain in Adults: Evaluation and Management (2024)
  • 7.9.3. WHO Guideline for Non-Surgical Management of Chronic Primary Low Back Pain in Adults in Primary and Community Care Settings (2023)
  • 7.9.4. Clinical Practice Guidelines for the Management of Chronic Pain: The Japanese Society for the Study of Low Back Pain (2021)
  • 7.9.5. Interventions for the Management of Chronic Low Back Pain: American Physical Therapy Association (APTA): (Revision 2021)
  • 7.9.6. North American Spine Society: Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care (2020)
  • 7.9.7. Non-invasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians (2017)
  • 7.9.8. European Guidelines for the Management of Chronic Non-Specific Low Back Pain (2004)

8. Epidemiology and Patient Population: 7MM Analysis

• 8.1. Key Findings
• 8.2. Assumptions and Rationale
• 8.3. Country-Level Summary of Prevalent CLBP Cases in the 7MM
• 8.4. The United States
  • 8.4.1. CLBP Prevalent Cases in the United States
  • 8.4.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in the United States
  • 8.4.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in the United States
  • 8.4.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in the United States
  • 8.4.5. CLBP Cases by Gender in the United States
  • 8.4.6. CLBP Cases by Age-group in the United States
  • 8.4.7. Treated Mild and Moderate-to-Severe CLBP Cases in the United States
• 8.5. EU4 and the UK
  • 8.5.1. CLBP Prevalent Cases in EU4 and the UK
  • 8.5.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in EU4 and the UK
  • 8.5.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in EU4 and the UK
  • 8.5.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in EU4 and the UK
  • 8.5.5. CLBP Cases by Gender in EU4 and the UK
  • 8.5.6. CLBP Cases by Age-group in EU4 and the UK
  • 8.5.7. Treated Mild and Moderate-to-Severe CLBP Cases in EU4 and the UK
• 8.6. Japan
  • 8.6.1. CLBP Prevalent Cases in Japan
  • 8.6.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in Japan
  • 8.6.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Japan
  • 8.6.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Japan
  • 8.6.5. CLBP Cases by Gender in Japan
  • 8.6.6. CLBP Cases by Age-group in Japan
  • 8.6.7. Treated Mild and Moderate-to-Severe CLBP Cases in Japan

9. Patient Journey

10. Key Endpoints in CLBP Clinical Trials

11. Marketed Therapies

• 11.1. Competitive Landscape of CLBP Marketed Therapies
• 11.2. Oxycodone ER abuse-deterrent (XTAMPZA ER): Collegium Pharmaceutical
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Analyst's View
• 11.3. Buprenorphine Buccal Film (BELBUCA): Collegium Pharmaceutical
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trial
  • 11.3.5. Analyst's View
• 11.4. VER-01 (EXILBY): VERTANICAL
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trials
  • 11.4.5. Clinical Development
    • 11.4.5.1. Clinical trials information
  • 11.4.6. Analyst's View

12. Emerging Therapies

• 12.1. Competition Landscape of Emerging Therapies
• 12.2. SEMDEXA (SP-102): Semnur Pharmaceuticals (Scilex Holding)
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trial Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst's View
• 12.3. Retatrutide (LY3437943): Eli Lilly and Company
  • 12.3.1. Product Description
  • 12.3.2. Clinical Development
    • 12.3.2.1. Clinical Trial Information
  • 12.3.3. Analyst's View
• 12.4. Rebonuputemcel (IDCT): DiscGenics
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Development
    • 12.4.3.1. Clinical Trial Information
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst's Views
• 12.5. Vicatertide (SB-01): Spine Biopharma
  • 12.5.1. Product Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Development
    • 12.5.3.1. Clinical Trial Information
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Analyst's Views
• 12.6. Rexlemestrocel-L (MPC-06-ID): Mesoblast and Grunenthal
  • 12.6.1. Product Description
  • 12.6.2. Other Developmental Activities
  • 12.6.3. Clinical Development
    • 12.6.3.1. Clinical Trial Information
  • 12.6.4. Safety and Efficacy
  • 12.6.5. Analyst's View
• 12.7. BRTX-100: BioRestorative Therapies
  • 12.7.1. Product Description
  • 12.7.2. Other Developmental Activities
  • 12.7.3. Clinical Development
    • 12.7.3.1. Clinical Trial Information
  • 12.7.4. Safety and Efficacy
  • 12.7.5. Analyst's Views
• 12.8. Olastrocel (CELZ-201-DDT): Creative Medical Technology
  • 12.8.1. Product Description
  • 12.8.2. Other Developmental Activities
  • 12.8.3. Clinical Development
    • 12.8.3.1. Clinical Trial Information
  • 12.8.4. Safety and Efficacy
  • 12.8.5. Analyst's Views
• 12.9. Cebranopadol (TRN-228): Tris Pharma (Adneuris Therapeutics)
  • 12.9.1. Product Description
  • 12.9.2. Other Development Activities
  • 12.9.3. Clinical Development
    • 12.9.3.1. Clinical Trial Information
  • 12.9.4. Safety and Efficacy
  • 12.9.5. Analyst's View
• 12.10. AMG0103 (NF-?B decoy oligonucleotide): AnGes and Shionogi
  • 12.10.1. Product Description
  • 12.10.2. Other Developmental Activities
  • 12.10.3. Clinical Development
    • 12.10.3.1. Clinical Trial Information
  • 12.10.4. Safety and Efficacy
  • 12.10.5. Analyst's Views
• 12.11. PP353: Persica Pharmaceuticals
  • 12.11.1. Product Description
  • 12.11.2. Other Developmental Activities
  • 12.11.3. Clinical Development
    • 12.11.3.1. Clinical Trial Information
  • 12.11.4. Safety and Efficacy
  • 12.11.5. Analyst's Views
• 12.12. KLS-2031: Kolon Life Science
  • 12.12.1. Product Description
  • 12.12.2. Other Developmental Activities
  • 12.12.3. Clinical Development
    • 12.12.3.1. Clinical Trial Information
  • 12.12.4. Safety and Efficacy
  • 12.12.5. Analyst's View

13. Chronic Lower Back Pain (CLBP): 7MM Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions
  • 13.4.2. Forecast Assumptions: Launch, Probability-Adjusted Peak Share, Years-to-Peak, and Uptake Type
• 13.5. The 7MM
  • 13.5.1. Total Market Size of CLBP by Country in the 7MM
  • 13.5.2. Market Size of CLBP by Therapies in the 7MM
• 13.6. The United States
  • 13.6.1. Total Market Size of CLBP in the United States
  • 13.6.2. Market Size of CLBP by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of CLBP in EU4 and the UK
  • 13.7.2. Market Size of CLBP by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of CLBP in Japan
  • 13.8.2. Market Size of CLBP by Therapies in Japan

14. Unmet Needs Related to Chronic Lower Back Pain (CLBP)

15. SWOT Analysis of Chronic Lower Back Pain (CLBP)

16. KOL Views Related to Chronic Lower Back Pain (CLBP)

• 16.1. Expert/KOL Interview Highlights

17. Market Access and Reimbursement

• 17.1. Overview
  • 17.1.1. The United States
  • 17.1.2. In EU4 and the UK
    • 17.1.2.1. Germany
    • 17.1.2.2. France
    • 17.1.2.3. Italy
    • 17.1.2.4. Spain
    • 17.1.2.5. United Kingdom
  • 17.1.3. Japan
  • 17.1.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 17.2. Market Access and Reimbursement in CLBP
  • 17.2.1. Reimbursement Landscape and Evolving Payer Priorities
  • 17.2.2. Historical Reimbursement Challenges and Policy Evolution
  • 17.2.3. Key Payer Considerations for Emerging Therapies
    • 17.2.3.1. Payer Perspectives on Regenerative and Cell Therapies
    • 17.2.3.2. Payer Viewpoints, Coverage Criteria, and Strategic Implications for Emerging Therapies
    • 17.2.3.2.1. SEMDEXA (SP-102) - Physician-Administered Drug Reimbursement
    • 17.2.3.2.2. VER-01 (EXILBY) - Medical Cannabis Reimbursement
  • 17.2.4. Payer Step Edits and Reimbursement Hurdles
  • 17.2.5. Strategic Implications for Emerging Therapy Developers

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight